Results 81 to 90 of about 2,752 (194)

Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts

Respiratory Research, 2012
Background Small airway narrowing is an important pathology which impacts lung function in chronic obstructive pulmonary disease (COPD). The accumulation of fibroblasts and myofibroblasts contribute to inflammation, remodeling and fibrosis by production ...
Tannheimer Stacey L, Wright Clifford D, Salmon Michael   +2 more
doaj   +1 more source

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review

, 2013
Erminia Ridolo,1 Marcello Montagni,1 Elisa Olivieri,1 Gian Galeazzo Riario-Sforza,2 Cristoforo Incorvaia2 1Department of Clinical and Experimental Medicine, University of Parma, Parma, 2Pulmonary Rehabilitation Unit, ICP Hospital, Milan, Italy Abstract ...
Riario-Sforza GG, Olivieri E, Ridolo E, Montagni M, Incorvaia C   +4 more
core  

Once-daily indacaterol versus twice-daily salmeterol for COPD : a placebo-controlled comparison

, 2010
Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β(2)-agonist bronchodilator recently approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD).
A. Dogra, C. Lassen, R. Owen, R. Dahl, null null, B. Kramer, S. Centanni, O. Kornmann   +7 more
core   +1 more source

Indacaterol versus Placebo on FEV1 at 12 weeks.

, 2013
Indacaterol versus Placebo on FEV1 at 12 weeks.
Polly H. X. Ma (115746), Wilson W. S. Tam (288770), David S. C. Hui (341922), Jin Ling Tang (445464), Vincent C. H. Chung (115743)   +4 more
core   +1 more source

Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety

Therapeutic Advances in Respiratory Disease, 2015
The international guidelines on chronic obstructive pulmonary disease (COPD) recommend inhaled bronchodilators for maintenance treatment of the disease. These drugs include β2-agonists and muscarinic antagonists, which are both available as short-acting ...
Erminia Ridolo, Marcello Montagni, Gian Galeazzo Riario-Sforza, Marco Baroni, Cristoforo Incorvaia   +4 more
doaj   +1 more source

Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study

, 2017
Cheong-Ju Kim,1 Hyoung-Kyu Yoon,2 Myung-Jae Park,3 Kwang-Ha Yoo,4 Ki-Suck Jung,5 Jeong-Woong Park,6 Seong Yong Lim,7 Jae Jeong Shim,8 Yong Chul Lee,9 Young-Sam Kim,10 Yeon-Mok Oh,11 Song Kim,12 Chul-Gyu Yoo13 1Department of Internal Medicine, National ...
Park MJ, Yoo CG, Yoo KH, Kim CJ, Yoon HK, Lee YC, Kim S, Shim JJ, Oh YM, Park JW, Jung KS, Lim SY, Kim YS   +12 more
core  

Indacaterol versus Tiotropium on SGRQ at week 26.

, 2015
(A) Pooled standardized difference in means for SGRQ total score at week 26 with 95% CIs of eligible studies comparing indacaterol vs tiotropium. (B) Pooled odds ratio for percentage of patients with MCID (decrease ≥ 4 units) of SGRQ total score at week ...
Yeon-Mok Oh (709680), Yong Bum Park (709682), Hye Yun Park (404092), Jung Soo Kim (311873), Seong Yong Lim (709679), Kwang Ha Yoo (709681), Seung Soo Sheen (709683), Ji Ye Jung (709685), Min-Ji Kim (280727), Jinkyeong Park (709678), K. C. Carriere (709684)   +10 more
core   +1 more source

New developments in the management of COPD: clinical utility of indacaterol 75 µg

International Journal of COPD, 2013
Paschalis Steiropoulos,1 Kostas Archontogeorgis,1 Evangelia Nena,2 Demosthenes Bouros1 1Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece; 2Laboratory of Hygiene and Environmental Protection, Medical ...
Steiropoulos P, Archontogeorgis K, Nena E, Bouros D   +3 more
doaj  

Indacaterol

COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011
James F, Donohue, Fernando J, Martinez
openaire   +2 more sources

Indacaterol

Österreichische Apothekerzeitung, 2006
europepmc   +2 more sources